Cytosorbents Corporation – NASDAQ:CTSO
Cytosorbents stock price today
Cytosorbents stock price monthly change
Cytosorbents stock price quarterly change
Cytosorbents stock price yearly change
Cytosorbents key metrics
Market Cap | 49.89M |
Enterprise value | 125.37M |
P/E | -4.56 |
EV/Sales | 4.27 |
EV/EBITDA | -3.84 |
Price/Sales | 4.40 |
Price/Book | 3.65 |
PEG ratio | 0.14 |
EPS | -0.59 |
Revenue | 34.28M |
EBITDA | -26.65M |
Income | -27.53M |
Revenue Q/Q | 23.72% |
Revenue Y/Y | 16.81% |
Profit margin | -111.76% |
Oper. margin | -107.36% |
Gross margin | 52.47% |
EBIT margin | -107.36% |
EBITDA margin | -77.75% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCytosorbents stock price history
Cytosorbents stock forecast
Cytosorbents financial statements
| Jun 2023 | 8.07M | -6.15M | -76.22% |
|---|---|---|---|
| Sep 2023 | 7.75M | -9.19M | -118.56% |
| Dec 2023 | 8.66M | -5.83M | -67.31% |
| Mar 2024 | 9.78M | -6.35M | -64.97% |
| Dec 2023 | 8.66M | -5.83M | -67.31% |
|---|---|---|---|
| Mar 2024 | 9.78M | -6.35M | -64.97% |
| Oct 2025 | 12.9M | -1.62M | -12.62% |
| Dec 2025 | 13.4M | -1.62M | -12.15% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 52444767 | 28.35M | 54.06% |
|---|---|---|---|
| Sep 2023 | 47575000 | 29.06M | 61.09% |
| Dec 2023 | 53260634 | 29.98M | 56.3% |
| Mar 2024 | 47070605 | 28.14M | 59.79% |
| Jun 2023 | -6.93M | 140.28K | 931.11K |
|---|---|---|---|
| Sep 2023 | -5.20M | -257.71K | 648.32K |
| Dec 2023 | -6.40M | -135.92K | 12.21M |
| Mar 2024 | -4.82M | -127.01K | -571.76K |
Cytosorbents alternative data
| Aug 2023 | 198 |
|---|---|
| Sep 2023 | 198 |
| Oct 2023 | 198 |
| Nov 2023 | 198 |
| Dec 2023 | 198 |
| Jan 2024 | 198 |
| Feb 2024 | 198 |
| Mar 2024 | 186 |
| Apr 2024 | 186 |
| May 2024 | 186 |
| Jun 2024 | 186 |
| Jul 2024 | 186 |
Cytosorbents other data
| Period | Buy | Sel |
|---|---|---|
| Dec 2024 | 51363 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | MARIANI PETER J officer: Chief Fi.. | Common Stock | 20,000 | $0.97 | $19,300 | ||
Purchase | MARIANI PETER J officer: Chief Fi.. | Common Stock | 20,000 | $0.97 | $19,300 | ||
Purchase | MARIANI PETER J officer: Chief Fi.. | Common Stock | 20,000 | $0.89 | $17,880 | ||
Purchase | MARIANI PETER J officer: Chief Fi.. | Common Stock | 20,000 | $0.89 | $17,880 | ||
Purchase | MARIANI PETER J officer: Chief Fi.. | Common Stock | 11,363 | $0.89 | $10,102 | ||
Purchase | MARIANI PETER J officer: Chief Fi.. | Common Stock | 11,363 | $0.89 | $10,102 | ||
Purchase | SOBEL ALAN D. director | Common Stock | 22,557 | $1.33 | $30,001 | ||
Purchase | SOBEL ALAN D. director | Common Stock Warrant (Right to Buy) | 7,894 | $2 | $15,788 | ||
Purchase | DELIARGYRIS EFTHYMIOS officer: Chief Medical Officer | Common Stock | 22,557 | $1.33 | $30,001 | ||
Purchase | DELIARGYRIS EFTHYMIOS officer: Chief Medical Officer | Common Stock Warrant (Right to Buy) | 7,894 | $2 | $15,788 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 14 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 1 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Phillip P. Chan (1970) Chief Executive Officer & Director | $728,080 |
Mr. Vincent J. Capponi M.S., MS (1958) Pres & Chief Operating Officer | $597,210 |
Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D. (1968) Chief Medical Officer | $490,110 |
Ms. Kathleen P. Bloch CPA, M.B.A., MBA, CPA (1955) Chief Financial Officer & Sec. | $487,850 |
-
What's the price of Cytosorbents stock today?
One share of Cytosorbents stock can currently be purchased for approximately $1.08.
-
When is Cytosorbents's next earnings date?
Unfortunately, Cytosorbents's (CTSO) next earnings date is currently unknown.
-
Does Cytosorbents pay dividends?
No, Cytosorbents does not pay dividends.
-
How much money does Cytosorbents make?
Cytosorbents has a market capitalization of 49.89M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 23.81% to 36.35M US dollars.
-
What is Cytosorbents's stock symbol?
Cytosorbents Corporation is traded on the NASDAQ under the ticker symbol "CTSO".
-
What is Cytosorbents's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Cytosorbents?
Shares of Cytosorbents can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cytosorbents's key executives?
Cytosorbents's management team includes the following people:
- Dr. Phillip P. Chan Chief Executive Officer & Director(age: 55, pay: $728,080)
- Mr. Vincent J. Capponi M.S., MS Pres & Chief Operating Officer(age: 67, pay: $597,210)
- Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D. Chief Medical Officer(age: 57, pay: $490,110)
- Ms. Kathleen P. Bloch CPA, M.B.A., MBA, CPA Chief Financial Officer & Sec.(age: 70, pay: $487,850)
-
How many employees does Cytosorbents have?
As Jul 2024, Cytosorbents employs 186 workers.
-
When Cytosorbents went public?
Cytosorbents Corporation is publicly traded company for more then 19 years since IPO on 8 Aug 2006.
-
What is Cytosorbents's official website?
The official website for Cytosorbents is cytosorbents.com.
-
Where are Cytosorbents's headquarters?
Cytosorbents is headquartered at 305 College Road East, Princeton, NJ.
-
How can i contact Cytosorbents?
Cytosorbents's mailing address is 305 College Road East, Princeton, NJ and company can be reached via phone at +7 323298885.
Cytosorbents company profile:
Cytosorbents Corporation
cytosorbents.comNASDAQ
186
Medical - Devices
Healthcare
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Princeton, NJ 08540
CIK: 0001175151
ISIN: US23283X2062
CUSIP: 23283X206
